Loading
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Previous close
$222.69
−$5.72 · -2.50%
After-hours
$222.52
−$0.17 · -0.08%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Day range
Current $222.69
52-week range
Current $222.69
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
65
Undervalued
Sentiment
63
Bullish
Risk
29
Moderate Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Day range
Current $222.69
52-week range
Current $222.69
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 691.71M EUR | 363.64M EUR | 266.72M EUR | 51.17M EUR | 7.78M EUR |
| Cost of goods sold | 103.18M EUR | 44.26M EUR | 44.4M EUR | 12.14M EUR | 3.52M EUR |
| Gross profit | 588.53M EUR | 319.38M EUR | 222.32M EUR | 39.04M EUR | 4.26M EUR |
| Research and development | 283.5M EUR | 307M EUR | 413.45M EUR | 379.62M EUR | 295.87M EUR |
| Selling, general, and administrative | 435.92M EUR | 284.55M EUR | 258.79M EUR | 215.85M EUR | 160.18M EUR |
| Operating expenses | 719.42M EUR | 598.15M EUR | 677.86M EUR | 600.85M EUR | 456.05M EUR |
| Interest income | 14.7M EUR | 14.36M EUR | 16.86M EUR | 7.43M EUR | 692K EUR |
| Interest expense | 77.46M EUR | 65.5M EUR | 44.07M EUR | 30.68M EUR | 3.91M EUR |
| Depreciation and amortization | 17M EUR | 17.71M EUR | 18.91M EUR | 17.96M EUR | 15.39M EUR |
| Operating income | −130.89M EUR | −278.76M EUR | −455.54M EUR | −561.81M EUR | −451.79M EUR |
| Net income | −219.03M EUR | −378.08M EUR | −481.45M EUR | −583.19M EUR | −383.58M EUR |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$317.42
42.54% upsideFunds reporting this stock among their holdings, ordered by reported position size.
T. Rowe Capital Appreciation Equity ETFTCAF173.68M1.92%9.09B USD0.31%$43.20-0.58%
iShares Biotechnology ETFIBB106.54M1.02%10.41B USD0.44%$200.48-1.41%
iShares Russell Mid-Cap Growth ETFIWP64.67M0.33%19.88B USD0.23%$140.9-0.40%
iShares Russell Mid-Cap ETFIWR50.23M0.09%55.97B USD0.18%$108.87+0.37%
iShares Russell 1000 Growth ETFIWF43.11M0.03%131.46B USD0.18%$127.11-1.28%
Sapient Quality Select ETFSQS32.33M2.26%1.41B USD0.80%$28.3768-0.99%
Vanguard Russell 1000 Growth ETFVONG20.13M0.04%54.3B USD0.06%$130.87-1.30%
First Trust Health Care AlphaDEX FundFXH15.18M1.35%1.12B USD0.61%$128.39-0.32%T. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFSapient Quality Select ETFSQSVanguard Russell 1000 Growth ETFVONGFirst Trust Health Care AlphaDEX FundFXHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
